Halozyme Appoints Former CFO David Ramsay as Interim Chief Financial Officer
HALO sits 40% above its 52-week low of $47.5.
Summary
Halozyme Therapeutics appointed David Ramsay, a former CFO, as Interim Chief Financial Officer, providing experienced leadership during the search for a permanent replacement.
Key Events · Executive and Board Changes · HALO
-
Interim CFO Appointed
David Ramsay has been appointed Interim Chief Financial Officer, effective March 23, 2026, while the company conducts an active search for a permanent CFO.
-
Experienced Leader Returns
Mr. Ramsay previously served as Halozyme's CFO from 2003-2009 and 2013-2015, bringing deep institutional knowledge and financial expertise to the role.
-
Compensation Package Detailed
Mr. Ramsay will receive a monthly salary of $50,000 and an initial equity grant of 10,000 restricted stock units (RSUs), with potential for an additional 2,500 RSUs if his interim service extends beyond July 1, 2026.
Analysis · HALO · Life Sciences
Halozyme Therapeutics has appointed David Ramsay, a former CFO of the company, as its Interim Chief Financial Officer. This move provides critical stability and continuity in financial leadership during the ongoing search for a permanent CFO. Mr. Ramsay's extensive prior experience with Halozyme, including guiding the company through significant growth, is a positive signal, ensuring that financial operations remain in capable hands following recent positive news regarding FDA approvals and ongoing strategic initiatives.
At the time of this filing, HALO was trading at $66.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $47.50 to $82.22. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.